Limitations
This analysis considered only a limited number of demographic and
clinical factors so clinical characteristics of subjects predicting a
therapeutic response to Benralizumab could not be adequately assessed.
Other limitations are the small number of subjects enrolled and the
single blind pilot study design. Although this was a small study, there
was an adequate power to predict a clinical significance in the UAS7
primary endpoint. With respect to the study design, it should be
emphasized that pilot studies represent a fundamental phase of the
clinical research process and are essential for determining the
feasibility of pursing a larger clinical trial 50which is supported by the results of this study.